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1. Introduction
The use of image-guided locoregional therapies (LRTs) plays a key role in the management of
patients with hepatocellular carcinoma (HCC). These therapies, classically used for palliation,
are now more frequently being used with curative intent either as a bridge before the definitive
therapy (surgical resection or orthotopic liver transplantation) or as a sole or combined therapy
in selected patients for whom surgical options are precluded [1-3]. The refinement and
development of new imaging technologies combined with recent advances in catheter
technology, embolic agents, chemotherapeutic drugs, and delivery systems have been linked
to further improved patients’ outcomes, thus increasing the interest in this approach. In the
first part of this chapter, an overview of the current available image-guided LRTs will be given.
In the second part, indications for different LRTs according to tumor stage will be discussed.
The third section will discuss the pivotal role of follow-up diagnostic imaging in the pre- and
post-procedural care of patients with HCC. Finally, future directions with regard to the use of
LRTs will also be presented and discussed.
2. Overview of currently available image-guided LRT options
2.1. Transarterial therapies
2.1.1. Chemoembolization
Hepatic transarterial embolization for the treatment of liver tumors was first performed in
the 1970s to  improve local  disease control.  The rationale  behind this  approach emerged
from the peculiarities of blood flow to HCC, which is supplied preferentially via the hepatic
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artery  owing  to  the  intense  angiogenesis  during  disease  progression.  For  transarterial
chemoembolization (TACE), first described in 1977 by Yamada [4], one or more chemother‐
apeutic drugs are added to the embolic agent, on the basis of the theory that tumor ischemia
caused by embolization of the dominant arterial supply has a synergistic effect with the
chemotherapeutic drugs. Several chemotherapeutic agents are used for TACE, the two most
commonly used doxorubicin and cisplatin, which can be mixed with one or several different
embolic  agents.  Recently,  the  development  of  calibrated  microparticles  loaded  with
doxorubicin  (DEBDOX-TACE) have gained acceptance.  These  drug-eluting microspheres
allow more reliable distal occlusion of small vessels and delivery of high-dose chemother‐
apy to the tumor with a very low systemic circulation of the chemotherapeutic agent. A
randomized  phase  II  study  [6]  comparing  conventional  TACE  with  DEBDOX-TACE
demonstrated a significant reduction in liver toxicity and serious adverse drug events in
the latter arm and an insignificant trend of better antitumoral effect [5, 6].
2.1.2. Yttrium-90 microsphere radioembolization
Transarterial radioembolization (TARE) is the transcatheter arterial delivery of microspheres
loaded with yttrium-90 (90Y), a pure beta emitter with a physical half-life of 64.2 hours, after
which it decays into stable zirconium. Like other transarterial therapies, TARE relies on the
preferential arterial supply and enhanced microvascular density of hepatic neoplasms [7, 8].
Acting as carriers, these biocompatible microspheres can conceptually deliver radiation
preferentially to tumors following hepatic artery delivery via embolization in the tumor-
related arterioles. Additionally, employing high-energy beta radiation instead of traditional
gamma radiation can potentially create an intense local radiotherapeutic effect that is propor‐
tional to the density of microsphere distribution. Hence, compared to nonselective extracor‐
poreal x-ray radiotherapy, TARE allows the particles to be deposited predominantly within
the tumor vasculature, thereby leading to tumor damage while preserving the surrounding
liver parenchyma. This critical feature allows the delivery of substantially higher radiation
doses than those that can be safely delivered via external beam radiotherapy.
In the United States, two Food and Drug Administration (FDA)-approved 90Y microsphere
products are in current clinical use: TheraSphere® (MDS Nordion Inc., Kanata, Ontario,
Canada), which consists of glass microspheres, and the resin-based SIR-Spheres™ (SIRTeX
Medical Ltd., Sydney, New South Wales, Australia). The glass 90Y microspheres are approved
in the United States for use in radiation treatment or as a neoadjuvant treatment before surgery
or liver transplantation in patients with HCC under the auspices of a humanitarian device
FDA exemption for orphan devices. TheraSphere has been used for neoplasia other than HCC
under compassionate circumstances after adherence to FDA-related guidelines. The resin 90Y
microspheres have premarket approval for the treatment of hepatic metastasis from colorectal
primary cancers with adjuvant hepatic arterial infusion of floxuridine. However, globally, the
regulatory approval of both products is more generic, and they also commonly used for HCC
therapy. The use of resin microspheres for an indication not included in the US FDA-specific
labeling is considered off-label use. Clinicians should consult and adhere to their institutional
and regulatory agencies before prescribing the treatment for off-label use with either device.
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2.1.3. Embolization with 131iodine
The use of radioactive iodine (131I) has been proposed for internal radiotherapy for HCC. In
this technique, ethiodized oil is tagged to the 131I via an atom-atom exchange. 131I-lipiodol then
emits gamma radiation with energy of 374 KeV and penetration of up to 0.4 mm. The retention
of lipiodol inside the HCC tumor cells allows a targeted dose-intensified radiation therapy to
be delivered. Despite the reported efficacy of 131I-lipiodol [9, 10], its use in routine daily practice
is limited owing to the lack of additional data and the complexity of this procedure when
compared with other available therapies such as TACE and TARE. Patients are also required
to be isolated for several days after the procedure for radiation safety. An initial randomized
study comparing internal 131I-lipiodol radiation therapy versus supportive care in patients with
HCC and portal vein thrombosis suggested the former conferred a survival benefit [9].
Considering the lack of clinical evidence and the possible severe side effects such as liver failure
and pneumonia related to its use, this treatment method deserves further analysis.
2.2. Percutaneous ablative therapies
2.2.1. Ethanol injection
Percutaneous ethanol injection (PEI)  is  the prototypical  technique used for percutaneous
ablation.  On this  technique,  absolute ethanol  is  injected inside the tumor and around it
using a guiding needle inducing coagulative necrosis as a result of cell dehydration, protein
denaturation and chemical occlusion of small vessels. PEI is a well-established technique
for treating nodular types HCCs with the extent of  necrosis  obtained via this  technique
intrinsically correlated with the size of the lesions with complete necrosis achieved in 90%,
70%,  and 50% of  tumors  measuring <2  cm,  2-3  cm,  and 3-5  cm,  respectively  [11-13].  A
possible explanation for the suboptimal response of larger tumors to PEI is the presence of
intratumoral  septa  and/or  a  capsule  that  blocks  the  diffusion  of  ethanol.  Recently,  the
introduction of a specific multipronged injection needle (Quadrafuse, RexMedical, Philadel‐
phia,  PE)  for  single-session  PEI  has  resulted  in  a  sustained  complete  response  rate  of
80%-90% in tumors measuring < 4cm [14].
2.2.2. Radiofrequency ablation
Radiofrequency ablation (RFA) has become the first-line choice for percutaneous ablation and
has superseded PEI as the method of choice for ablative LRT mainly because it yields complete
necrosis with fewer sessions than required for PEI, especially in larger tumors, thus leading to
better local disease control [15-19]. This technology relies on its physical characteristics to
deliver an alternating electrical current within the lesion via an electrode needle placed directly
into the tumor. The resulting frictional heat and movement of electrons within the lesion and
surrounding tissues generate heat in the immediate vicinity of the electrode which is then
conducted to the surrounding environment, thereby resulting in the coagulative necrosis of a
predetermined volume of tissue. RFA is performed by connecting a generator that provides
an electric current to a metallic applicator probe (needle), which is inserted into the tumor
percutaneously via computed tomography, fluoroscopy, magnetic resonance imaging, or
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ultrasound guidance. Thermal energy is applied to tissues through the tip of the probe. The
tissues surrounding the tip are destroyed within seconds as temperatures reach 55°- 60°C. Care
is taken to avoid charring tissues, which limits heat propagation. Ideally, the ablation zone
should encompass the tumor and a 5-10-mm margin of normal tissue, which might eliminate
small, undetected satellite lesions. The size and shape of the ablation zone vary depending on
the amount of energy, the type and number of electrodes, the duration of ablation, and inherent
tissue characteristics [20].
Initial RFA indications included the treatment of small lesions (<3cm) in patients who were
not surgical candidates and the palliation of large lesions. However, owing to the efficacy and
safety profile of the technique, its use has greatly expanded and it is now offered to patients
who are surgical candidates with comparable 5 year survival outcomes to resection [21]. The
limitations of the technique include a “heat-sink” effect, whereby adjacent blood vessels
produce perfusion-mediated attenuation of thermal energy deposition, potentially leading to
incomplete ablation; large (>5 cm) lesions; and proximity to thermal sensitive structures, such
as the gastrointestinal wall, gallbladder, diaphragm, and nerves.
2.2.3. Microwave ablation
Microwave ablation (MW) is an emerging hyperthermic ablative therapy that is a valuable
alternative to RFA for the ablation of HCC. Several MW systems have been approved for
clinical use in the United States [22], comprised by an energy generator that is connected via
a coaxial cable to a percutaneous needle(s) that functions as an active antenna that delivers
energy within the tumor. The application of electromagnetic microwaves in the matter creates
heat by agitating water molecules in the surrounding tissue, thereby producing friction and
heat and inducing cellular destruction via coagulative necrosis [23]. Compared with other
available ablative technologies, MW creates larger tumor ablation volumes with consistently
higher intratumoral temperatures, has faster ablation times, and an improved and a more
favorable convection profile [22], thus resulting in a reduction in the “heat sink” effect created
by vessels in proximity to the ablated zone [24]. Recent advances in MW engineering have
resulted in better MW systems with the potential for creating more effective ablation zones.
2.2.4. Cryoablation
The application of freezing temperatures to tumors can be also utilized to cause tissue
destruction. Similarly to RFA and MW, a cryoablation probe is directly inserted into the target
lesion. Argon circulates through the probe, causing a rapid drop in the local temperature
around the probe, promoting local ischemia and a disruption of the cellular membrane. Ice
crystals form within the cells and adjacent interstitium, causing cell dehydration and sur‐
rounding vascular thrombosis. Subsequently, when the tissues thaw, vascular occlusion leads
to further ischemic injury [25]. Consistent tumor cell death is accomplished when the tissues
are exposed to temperatures of at least -20ºC within an area of approximately 3 mm inside the
margins of the ice ball. As with RFA, the main limitations of cryoablation include proximity
of the lesion to blood vessels, gastrointestinal organs, nerves, and skin. Treatment of large
tumor volumes with cryoablation can lead to the development of rare but serious systemic
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complications, such as ‘cryoshock’, a cytokine-mediated inflammatory response associated
with coagulopathy and multiorgan failure, myoglobinuria, and severe thrombocytopenia
[26-28]. Otherwise, most complications of cryotherapy are generally similar to those of RFA,
such as hemorrhage and injury to adjacent organs.
2.3. Combination therapies
The use of combined therapies, either a combination of different LRTs or LRT combined with
systemic therapies, has gained particular attention in the last decade. Combining different
modalities of LRT such as RFA and chemoembolization could increase the treatment success
rate, particularly in large HCCs [29]. The rationale for this approach lies in the devasculariza‐
tion of large HCCs via embolization or chemoembolization, which reduces the possibility of
having a deleterious “heat sink” effect in hypervascular tumors treated with RFA and thereby
increases its therapeutic effect. This approach has been validated in several studies that
demonstrated larger ablation zones when bland embolization or chemoembolization was
performed before the ablative treatment [30-32]. Moreover, performing RFA before chemo‐
embolization has been shown to increase the deposition of the chemoembolic agent in the
periphery of the ablated tumor, the most common area for disease recurrence [33].
It is also suggested that the hypoxic environment after TACE may trigger the expression of
neoangiogenic factors such as the vascular endothelial growth factor (VEGF), possibly leading
to tumor growth and progression. Therefore, to avoid the development of a neoangiogenesis
cascade and, by consequence, tumor progression systemic therapies in the form of chemo‐
therapy or antiangiogenic drugs with the intent of acting in different fronts of neoangiogenesis
have been proposed.
3. LRT for HCC according to disease stage
To review the available LRTs according to different stages of disease, we used the Barcelona
Clinic Liver Cancer (BCLC) staging system, which has emerged in recent years as the standard
means of classifying HCC. In this system, cases are classified into 5 different stages – very early
(0), early (A), intermediate (B), advanced (C), and terminal (D) – according to pre-estabilished
prognostic variables, thereby allowing therapies to be allocated according to treatment-related
status (Figure 1). Terminal-stage treatment options are beyond the scope of this chapter, as
LRTs are not administered in that setting.
3.1. Very early stage (0)
Patients diagnosed with very early-stage disease (performance status: 0, Child-Pugh score:
A,  single HCC <2 cm) on the BCLC staging system have the highest  potential  for  cure.
Surgical resection is the modality of choice for this stage and yields a 5-year survival rate
of around 75% in these patients, with the anatomic resection–defined as the en bloc removal
of a portion of liver supplied by a major branch of the portal vein and the hepatic artery
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utilized as the preferred surgical  technique [34,  35].  Despite the improvements achieved
with recent refinements in surgical technique and postoperative care, which resulted in a
low mortality rate of 1%-3%, anatomic resection in patients with very early HCC is still
limited depending on the volume of segments that need to be resected. Nodules smaller
than 2 cm that are not subcapsular, perivascular, or adjacent to the gallbladder are the ideal
indication for ablative therapies, and RFA is the standard technique in many institutions
[2,  36,  37].  In  a  recent  study,  Cho and colleagues  [38]  concluded that  RFA and hepatic
resection are equally effective for the treatment of stage 0 HCC. Livraghi and colleagues
[19] reported a complete response rate of 97.2% and a 5-year survival rate of 68% in 218
patients with very early-stage HCC treated using RFA. In another recent study [39] of 83
patients with very early HCC who were treated using different modalities of percutane‐
ous ablation (33 PEI, 19 MW, and 31 RFA), the complete response rate was 95%, and the
5-year survival  rate was 78%. Therefore,  RFA is  suggested by some authors as first-line
therapy for very early-stage HCC, and surgical resection is reserved for when individual
patient  variables  render  RFA unfeasible  or  unsafe  [40].  In  selected  cases  of  very  early-
stage HCC, when surgery or RFA cannot be offered because of increased bilirubin level,
signs of portal hypertension, and risky tumor location, such as pericholecystic lesions and
lesions near the hilum, PEI can still be offered as an alternative.
Figure 1. BCLC staging system and treatment strategy, 2011 [2]
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3.2. Early stage (A)
Patients with a solitary HCC or up to three lesions measuring less than 3 cm without associated
diseases are the ideal candidates to be effectively treated with liver transplantation. On those
where associated disease exists or where bridge therapy is required before liver transplanta‐
tion, percutaneous ablation (PEI/RFA) is the modality of choice. Compared with PEI, RFA is
consistently more effective and renders better local disease control. It also offers a survival
benefit compared with PEI, as demonstrated by three independent meta-analyses that revealed
5-year survival rates of 51%-64% in patients who met the BCLC criteria for surgical resection
[41-43].
MW ablation is emerging as a viable alternative to RFA in patients with early-stage HCC owing
to its larger tumor ablation volumes, because the inherent characteristics of this technique are
less affected by the “heat-sink” effect created by vessels in proximity to the tumor. To date,
the only randomized control trial comparing RFA and MW ablation did not reveal any
differences in the effectiveness of the two techniques, with a trend toward RFA in respect
achieving tumor ablation in fewer sessions [44]. Nevertheless, the recent advances in MW
engineering along with improvements in the learning curve of this technology will potentially
create a more effective ablation zone and better local disease control when compared to RFA.
Although not specified in the BCLC guidelines, a combination of ablative and transarterial
treatments could be considered for cases in which the target lesion measures between 3 and 5
cm in its longest axis in view of the suboptimal response of larger lesions to ablative therapies
alone [30, 31, 45, 46]. The recent results of a randomized control trial [46] accessing the efficacy
of combining RFA with subsequent conventional TACE (lipiodol plus epirubicin at 30-50 mg
followed by introduction of gelatin sponge) in patients with HCCs measuring 3.1-5.0 cm
showed that the rate of tumor progression was significantly lower in the combination group
than in the ablation-only group (39% versus 6%, P=0.012) [46]. DEB-TACE administered after
RFA has also been studied and yielded a potential increase of 60.9%+-39.0 in treatment-induced
necrosis on imaging [33]. Further studies to determine the ideal sequence of techniques and
the real impact of this approach are needed.
When percutaneous ablative therapies such as RFA and MW are not feasible or safe, TACE
can be performed as an alternative. This can be a valuable tool in patients with solitary large
(>5 cm) lesions, for whom the benefits of combining different LRTs seems negligible. In a recent
study, DEB-TACE administered before liver transplantation yielded complete necrosis in 77%
of treated tumors on pathology (mean size: 3.2 cm+/-1.54 cm) with no serious adverse events
observed.
3.2.1. Intermediate stage (B)
TACE is the standard of care for patients with stage B disease, according to BCLC guidelines.
This indication is based on the improved survival rates demonstrated in a meta-analysis of six
randomized clinical trials that compared TACE with the best supportive care or suboptimal
therapies [47]. Of note, however, the studies included in this meta-analysis were considerably
heterogeneous (particularly with regard to the patient populations and the TACE techniques
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used), and the cases of intermediate-stage HCC comprised a heterogeneous population of
patients whose liver function and tumor burden varied widely. Therefore, not all patients
included in BCLC stage B will have the same benefits from TACE, as demonstrated by a recent
meta-analysis of randomized control trials [48]. On a recent study by Burrel et al [49], a median
survival of 42.8 months was achieved with the use of DEB-TACE in patients classified as BCLC-
B after censoring follow-up at the time of liver transplantation, sorafenib treatment and TARE.
A sub-stratification of this patient population, along with the comparison of TACE with other
LRTs and systemic therapies, should be encouraged in future research.
The combination of DEB-TACE with sorafenib in patients with intermediate-stage HCC was
assessed in a phase II randomized, double-blind, placebo-controlled trial. Patients who
received sorafenib combined with DEB-TACE had a longer time to progression than did the
control group, to whom DEB-TACE was administered in combination with placebo (hazard
ratio: 0.797). Nonetheless, the difference in median survival was only 3 days in favor of the
sorafenib group (169 versus 166 days), and the difference in overall survival between two
groups was 6 days in favor of the placebo group (562 versus 554 days). Evidence from ongoing
phase III trials is expected to clarify the clinical efficacy of this combination.
The use of radioembolization with 90Y in patients with intermediate to advanced stage HCC
has been investigated in a phase II study [50]. In this study, 17 patients with intermediate-stage
HCC without portal vein thrombosis were treated with a lobar delivery of 120 Gy. Nine (52.9%)
patients had complete response (CR) or partial response (PR) accordingly to the European
Association for the Study of Liver (EASL) criteria. Disease control (CR, PR or stable disease
[SD]) was achieved in 15 patients (88.2%). Time to progression was 13 months, and overall
survival was 18 months (range, 12–38 months) [50]. In a recent multicenter trial [51] assessing
the use of radioembolization with 90Y in patients with HCC, 87 patients with BCLC stage B
HCC treated with 90Y had a median survival of 16.9 months (95% CI 12.8-22.8). Of note, this
study demonstrated that radioembolization with 90Y appears to be particularly promising for
the subset of patients with intermediate-stage HCC who are considered poor candidates for
TACE (median survival: 15.4-16.6 months) as well for those for whom prior TACE or bland
embolization was ineffective (median, 15.4 months). The results of this study emphasize the
possibility of using radioembolizaiton as a complementary therapy to TACE in the HCC
armamentarium.
3.3. Advanced stage (Stage C)
According to the BCLC guidelines, the use of the systemic multi tyrosine-kinase inhibitor,
sorafenib, is the cornerstone for patients with advanced HCC [2]. The benefit of this therapy
was demonstrated in two randomized control trials [52, 53] in which this new therapy was
compared with placebo. Both studies revealed an improvement in the median overall survival
and the median time to disease progression on imaging. Although LRTs are not recommended
for patients with BCLC stage C disease, many patients who undergo LRT in the form of TACE
or radioembolization are in fact classified as having advanced-stage disease according to the
aforementioned criteria. This subclass of patients is characterized by the presence of tumoral
invasion of a branch vein with or without limited extra-hepatic disease and a performance
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status 1-2. Combination therapy using TACE and sorafenib is technically feasible and generally
well tolerated in patients with unresectable HCC [54-56]. In a recent phase II study of concur‐
rent conventional TACE and sorafenib, Park et al. [55] demonstrated a median time to
progression of 7.3 and 5 months for patients with BCLC stage B and C disease, respectively.
Compared with unpublished data from the same group, the combination of sorafenib with
conventional TACE yielded increased time to progression in both patients with BCLC stages
B and C when compared with conventional TACE (cTACE) alone (4.5 and 2.8 months,
respectively).
Concurrent therapy with DEB-TACE and sorafenib has also been investigated [56]. DEB-TACE
promotes a lesser degree of serum aminotransferase elevation than does conventional TACE,
which is the most common cause for delaying therapy with sorafenib. Of note, sorafenib should
ideally be administered as soon as possible after TACE is administered to to prevent an early
surge of vascular endothelial growth factor and other angiogenic factors. Pawlik et al. [56]
assessed the safety and response rate of combination therapy using DEB-TACE and sorafenib
in patients with advanced-stage HCC. The results of this study demonstrated that the combi‐
nation of sorafenib and DEB-TACE was well tolerated and safe, and most toxic effects related
to sorafenib were manageable with dose adjustment. Disease control was achieved in 95% of
patients (SD+PR), according to Response Evaluation Criteria in Solid Tumors (RECIST ) with
an objective response of 58% (according to the EASL).
4. Imaging response assessment for LRT
The RECIST and the world health organization (WHO) criteria are the standard criteria for
assessing imaging response in patients who undergo systemic therapies using cytotoxic drugs.
These criteria assess the response of target lesions solely on the basis of their measurement in
diameters and their changes after systemic therapy. In the setting of LRT, tumor response as
determined via by simple measurement in diameters is not accurate enough since tumor
necrosis, a common endpoint for all LRTs, is not taken into consideration.
The inconsistency of using these response evaluation criteria for systemic therapy in patients
undergoing LRTs was first addressed by a panel of experts on HCC from the European
Association Study of Liver in 2000, which suggested that response assessment should be based
on the estimation of the reduction in viable tumor, as recognized by arterial-phase enhance‐
ment on radiologic imaging. The concept of achieving complete necrosis (complete response)
after LRT is a good surrogate for excellent outcome and has been confirmed by a number of
different studies [57-60].
More recently, the addition of molecular targeted therapies such as sorafenib, bevacizumab,
and erlotinib to the anticancer armamentarium rendered an improvement in overall survival
without showing any significant imaging response rate according to the RECIST criteria [54,
61]. This finding can also be explained by the ability of these new agents to cause necrosis in
the target lesions without any significant significantly affecting the reduction of the size of the
lesions. In fact, it is now known that some lesions tend to increase in volume after the use of
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molecularly targeted therapies owing to the presence of massive necrosis and edema on their
interior.
Figure 2. TACE and magnetic resonance imaging follow-up utilizing the mRECIST: (A) Digital subtraction angiography
(DSA) demonstrating the hypervascular lesion (black arrow) located in the segment VI. (B) Parenchymal phase show‐
ing the encapsulated pattern of the lesion (black arrow). (C) post DEB-TACE DSA no longer characterizing the hyper‐
vascular tumor. (D)Baseline magnetic resonance imaging (MRI) showing the hypevascular tumor in the arterial phase
(white line) measuring 3.2 cm. (D) post DEB-TACE MRI arterial phase, showing the absence of arterial enhancement at
the lesion (white arrow) after the DEB-TACE, configuring acomplete response according to the mRECIST. Liver explant
analysis confirmed complete necrosis of the treated
To address all the limitations associated with the RECIST criteria in assessing therapy response,
especially that of HCC, novel imaging correlative endpointswere proposed by different
investigators [61-63]. One of the initial proposals created was the amendment of enhancement
criteria to the WHO criteria (EASL criteria), which use the enhancement observed in the arterial
phase by the intravenous contrast as a surrogate for viable tumor, whereas the absence of
arterial enhancement within the tumor indicates tumor necrosis. Despite the initial enthusi‐
asm, recent studies have demonstrated that these criteria cannot provide prognostic data to
enable differentiation between the survival outcomes of patients who achieved partial
response and those who had stable disease. This is possibly explained by the different
thresholds for therapy response extrapolated from the WHO criteria. Therefore, a new
proposal suggested for assessing therapy response for HCC was made by the modification of
the conventional RECIST criteria with the incorporation of the concept of viable tumor (Figure
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2). These criteria, also known as the modified RECIST (mRECIST) [63], have been demonstrat‐
ed to be an accurate tool for assessing response for both locoregional and systemic therapies
[59, 60, 64] and should be used as the method of choice for assessing treatment response in
patients with HCC [2]. Although mRECIST helps to predict survival outcomes in patients
undergoing LRTs, further data are needed to establish these criteria for assessing survival in
the setting of systemic therapies with molecularly targeted drugs. A summary of the different
response criteria are summarized in Figure 3.
Figure 3. Radiographic response criteria used to assess the clinical effects of HCC treatment [59]. Adapted from: Shim,
J.H., et al., Which response criteria best help predict survival of patients with hepatocellular carcinoma following che‐
moembolization? A validation study of old and new models. Adapted from Radiology, 2012. 262(2): p. 708-18.
5. Future directions
The last few decades were characterized by establishing the limits of outcomes of liver directed
therapies for HCC. Recent therapeutic advances exploiting molecular biological pathways
have created new vistas in our collective approaches towards this disease. Certain distinct
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clinical scenario will remain the focus of future endeavors such as recurrence and cancer
prevention. Tumor recurrences are a major drawback in patients with very early and early
stages HCC submitted to ablative therapies or resection. Effective preventive agents in the
form of better ablative technologies or combined loco-regional and systemic therapies are
needed given the projected increase in patients at risk for developing HCC. Irreversible
electroporation (IRE) is a new ablative therapy that increases cell membrane permeability by
changing the transmembrane potential and subsequently disrupts the lipid bilayer integrity
resulting in cell death [65, 66]. Currently there is one IRE system available on the market.
Similarly to an RFA system, this system consists of two major components: a generator that
delivers energy of up to 3000 V and a needle-like electrical probe. Compared with other
available ablative technologies, this technology can create a sharper boundary between the
treated and untreated area in vivo within microsecond or milliseconds; moreover, because it
is a non-thermal technique, issues associated with perfusion-mediated tissue cooling or
heating are not relevant. Preclinical investigations [67] focused on HCC have demonstrated
the great potential of this technology for targeted ablation of HCC and have prompted its
clinical evaluation.
Light-activated drug therapy uses light-emitting diodes to activate talaporfin sodium, a small
molecule synthesized from a chlorophyll derivate that has the ability to concentrate within the
tumors when administered intravenously and activated by placing a percutaneous light
emitter intratumorally under imaging guidance. Talaporfin is capable of absorbing long-
wavelength light, resulting in singlet oxygen that causes apoptotic cell death through oxidation
and permanent tumor vessel occlusion. Preclinical animal studies suggested that the produc‐
tion of large apoptotic masses in tumor with light-activated drug therapy yields tumor-specific
clones of CD8+ T cells which infiltrate distant, untreated tumors. A phase III clinical trial is
currently assessing the use of talaporfin for HCC.
In patients with advanced-stage HCC, future research will hopefully better delineate the
indications for TACE and TARE, either in the form of isolated therapy or combined with
sorafenib with possible improvements in slowing disease progression. Finally, advances in
molecular cell biology will identify new therapeutic strategies for patients with advanced-
stage HCC. For these advances to take place, a multidisciplinary continuous clinical and
experimental research is vital.
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